Global Bioartificial Kidney Market By Clinical Trial (Pre-Clinical, Phase I Clinical Trial, Others), By Application (Short-Term Solution Of Renal Dialysis, Longer-Term Of A Living Kidney Transplant, Polycystic Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS), Others), By End-User (Hospital, Organ Transplant Centers, Research Institutes, Others), By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Bioartificial kidneys are made up of a typical hemofilter connected in series with a bioreactor unit containing renal epithelial cells. The renal tubule epithelial cells should perform transport, metabolic, endocrinologic, and immunomodulatory tasks. The bioartificial kidney filters waste by convection, which uses the body's natural blood pressure to separate blood cells, proteins, and other major components from small toxins and waste particles that can fit through the hemofilter's pores. The integration of the silicon nano membrane hemofilter and the bioreactor with human kidney cells combines the best of both concepts in a bio hybrid approach, resulting in the "bioartificial" kidney, which contains both biological and entirely synthetic components. The increased incidence of renal failure and a long waiting list for kidney transplants are major factors that are expected to drive the growth of the global bioartificial kidney market in the near future.
The growing number of chronic kidney disease patients is one of the significant factors for the growth of the market. According to data from the Centers for Disease Control and Prevention, chronic kidney disease affects more than 1 in 7, or 15% of U.S. adults, or 37 million individuals, in the United States. As many as 9 out of 10 persons with CKD are unaware of their condition, and approximately 2 out of 5 adults with severe CKD are unaware of their condition. Moreover, the federal government, which is the principle payer for such patients' medical care, is pushing agencies to accelerate the development of technologies that could improve care. The Kidney Project has been chosen to participate in two FDA-sponsored programs, the Innovation Pathway 2.0 and the Expedited Access Pathway, both of which aim to reduce the time it takes to bring safe and effective technologies to the market. However, reimbursement issues, as well as the risks and problems associated with dialysis treatment, are hindering the growth of global bioartificial kidney market.
The novel coronavirus disease 2019 (COVID-19) has a high mortality rate among older adults and people suffering from chronic conditions such as chronic kidney disease (CKD). Despite the fact that numerous studies have lately indicated several techniques for the management of COVID-19 in CKD, its impact on individuals with renal illnesses remains the greatest challenge globally. Furthermore, patients with end-stage kidney illness were considered to be a largely susceptible group for COVID-19, with an infection prevalence of 16%. The prevalence of CKD in COVID-19 individuals has been estimated to be between 0.09% and 47.05%. Furthermore, rising promise of innovation in artificial kidney technology promises new potential for industry participants in the bioartificial kidney market to gain momentum.
In terms of revenue, the bioartificial kidney market is projected to grow at a CAGR of 36.87% over the forecast period (2022 – 2030). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Bioartificial Kidney Market Revenue & Forecast, (US$ Million), 2015 – 2030
Clinical Trial Outlook:
Based on clinical trial, the global bioartificial kidney market has been primarily segmented into pre-clinical, phase I clinical trial, and others. Key players from the market are in the pre-clinical stage such as the "bioartificial kidney" invented by the laboratory of H. David Humes, MD is a two-part device consisting of a blood circuit in which a commercial hemofilter is guided by a novel "Renal Assist Device" (RAD) containing living human cells. The FDA has approved a phase I clinical trial of the bioartificial kidney for the treatment of critically ill patients that are already in the intensive care unit (ICU) and are receiving Continuous Venovenous Hemofiltration (CVVH) for acute renal failure.
Application Outlook:
Based on application, the global bioartificial kidney market has been segmented into short-term solution of renal dialysis, longer-term of a living kidney transplant, polycystic kidney disease, focal segmental glomerulosclerosis (FSGS), and others. Scientists are working on developing an artificial kidney that can replicate the function of real organs and eliminate the need for dialysis. The University of California, San Francisco (UCSF) is developing an implantable artificial kidney that can directly replicate the functions of real kidneys. One of the most important applications of the bioartificial kidney is the ability to extend the life of a living kidney transplant.
End-User Outlook:
Based on end-user, the global bioartificial kidney market has been segmented into hospitals, organ transplant centers, research institutes, and others. A bioartificial kidney is in the developing phase, research centers and institutes are primarily focused on the development of this kidney in order to help patients live longer lives. Also, increasing research and development activities have contributed to market growth in recent decades, which is accounting for the major market share.
Region Outlook:
Based on regions, North America accounted for the largest market share in the bioartificial kidney market, owing to the increased adoption of advanced technologies and the presence of major players in the major economies such as the United States, Canada, and Mexico. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), more than 661,000 people in the United States had kidney failure in 2017, with 468,000 on dialysis. Furthermore, the bioartificial kidney market is expected to rise due to an increase in R&D activities in the healthcare sector to develop novel bioartificial kidneys.
Competitive Landscape Outlook:
The report provides both, qualitative and quantitative research of the global bioartificial kidney market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings, and specification amongst others.
Some of the players operating in the bioartificial kidney market are
- AWAK Technologies
- Blood Purification Technologies Inc.
- Dutch Kidney Foundation
- UCSF
- Other Market Participants
Global Bioartificial Kidney Market
- By Clinical Trial
- Pre-Clinical
- Phase I clinical trial
- Others
- By Application
- Short-term solution of renal dialysis
- Longer-term of a living kidney transplant
- Polycystic Kidney Disease
- Focal Segmental Glomerulosclerosis (FSGS)
- Others
- By End-User
- Hospital
- Organ Transplant Centers
- Research Institutes
- Others
- By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Table
of Contents
1. Market Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Forecast
Years: 2022 –
2030
2.
Key Target Audiences
3.
Research Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key
Opinion Leaders (KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market
Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation
Methodology
3.5. Research Assumptions
4.
Recommendations and Insights from AMI’s Perspective**
5.
Holistic Overview of Bioartificial Kidney Market
6.
Market Synopsis:
Bioartificial Kidney Market
7.
Bioartificial Kidney Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in Bioartificial
Kidney Market
7.4. Market
Determinants
Radar Chart
7.5. Macro-Economic and
Micro-Economic Indicators: Bioartificial Kidney Market
7.6. Industry Gross Margin Overview
7.7. Porter’s Five Force Analysis
7.8. Impact of Covid-19 on Bioartificial Kidney Market
8.
Global Bioartificial Kidney Market Analysis and Forecasts, 2022 – 2030
8.1. Overview
8.1.1. Global Bioartificial Kidney
Market Revenue (US$ Mn)
8.2. Global Bioartificial Kidney
Market Revenue (US$ Mn) and Forecasts,
By Clinical Trial
8.2.1. Pre-Clinical
8.2.1.1. Definition
8.2.1.2. Market
Forecast, 2022
- 2030
8.2.1.3. Compound Annual Growth Rate (CAGR)
8.2.1.4. Regional Bifurcation
8.2.1.4.1. North America
8.2.1.4.1.1. Market
Forecast, 2022
- 2030
8.2.1.4.2. Europe
8.2.1.4.2.1. Market
Forecast, 2022
- 2030
8.2.1.4.3. Asia Pacific
8.2.1.4.3.1. Market
Forecast, 2022
- 2030
8.2.1.4.4. Middle East and Africa
8.2.1.4.4.1. Market
Forecast, 2022
- 2030
8.2.1.4.5. Latin America
8.2.1.4.5.1. Market
Forecast, 2022
- 2030
8.2.2.
Phase I clinical trial
8.2.2.1. Definition
8.2.2.2. Market
Forecast, 2022
- 2030
8.2.2.3. Compound Annual Growth Rate (CAGR)
8.2.2.4. Regional Bifurcation
8.2.2.4.1. North America
8.2.2.4.1.1. Market
Forecast, 2022
- 2030
8.2.2.4.2. Europe
8.2.2.4.2.1. Market
Forecast, 2022
- 2030
8.2.2.4.3. Asia Pacific
8.2.2.4.3.1. Market
Forecast, 2022
- 2030
8.2.2.4.4. Middle East and Africa
8.2.2.4.4.1. Market
Forecast, 2022
- 2030
8.2.2.4.5. Latin America
8.2.2.4.5.1. Market
Forecast, 2022
- 2030
8.2.3. Others
8.2.3.1. Definition
8.2.3.2. Market
Forecast, 2022
- 2030
8.2.3.3. Compound Annual Growth Rate (CAGR)
8.2.3.4. Regional Bifurcation
8.2.3.4.1. North America
8.2.3.4.1.1. Market
Forecast, 2022
- 2030
8.2.3.4.2. Europe
8.2.3.4.2.1. Market
Forecast, 2022
- 2030
8.2.3.4.3. Asia Pacific
8.2.3.4.3.1. Market
Forecast, 2022
- 2030
8.2.3.4.4. Middle East and Africa
8.2.3.4.4.1. Market
Forecast, 2022
- 2030
8.2.3.4.5. Latin America
8.2.3.4.5.1. Market
Forecast, 2022
- 2030
8.3.
Key Segment for Channeling Investments
8.3.1. By Clinical Trial
9.
Global Bioartificial Kidney Market Analysis and Forecasts, 2022 – 2030
9.1. Overview
9.2. Global Bioartificial Kidney
Market Revenue (US$ Mn) and Forecasts,
By Application
9.2.1. Short-term solution of renal
dialysis
9.2.1.1. Definition
9.2.1.2. Market
Forecast, 2022
- 2030
9.2.1.3. Compound Annual Growth Rate (CAGR)
9.2.1.4. Regional Bifurcation
9.2.1.4.1. North America
9.2.1.4.1.1. Market
Forecast, 2022
- 2030
9.2.1.4.2. Europe
9.2.1.4.2.1. Market
Forecast, 2022
- 2030
9.2.1.4.3. Asia Pacific
9.2.1.4.3.1. Market
Forecast, 2022
- 2030
9.2.1.4.4. Middle East and Africa
9.2.1.4.4.1. Market
Forecast, 2022
- 2030
9.2.1.4.5. Latin America
9.2.1.4.5.1. Market
Forecast, 2022
- 2030
9.2.2. Longer-term of a living
kidney transplant
9.2.2.1. Definition
9.2.2.2. Market
Forecast, 2022
- 2030
9.2.2.3. Compound Annual Growth Rate (CAGR)
9.2.2.4. Regional Bifurcation
9.2.2.4.1. North America
9.2.2.4.1.1. Market
Forecast, 2022
- 2030
9.2.2.4.2. Europe
9.2.2.4.2.1. Market
Forecast, 2022
- 2030
9.2.2.4.3. Asia Pacific
9.2.2.4.3.1. Market
Forecast, 2022
- 2030
9.2.2.4.4. Middle East and Africa
9.2.2.4.4.1. Market
Forecast, 2022
- 2030
9.2.2.4.5. Latin America
9.2.2.4.5.1. Market
Forecast, 2022
- 2030
9.2.3. Polycystic Kidney Disease
9.2.3.1. Definition
9.2.3.2. Market
Forecast, 2022
- 2030
9.2.3.3. Compound Annual Growth Rate (CAGR)
9.2.3.4. Regional Bifurcation
9.2.3.4.1. North America
9.2.3.4.1.1. Market
Forecast, 2022
- 2030
9.2.3.4.2. Europe
9.2.3.4.2.1. Market
Forecast, 2022
- 2030
9.2.3.4.3. Asia Pacific
9.2.3.4.3.1. Market
Forecast, 2022
- 2030
9.2.3.4.4. Middle East and Africa
9.2.3.4.4.1. Market
Forecast, 2022
- 2030
9.2.3.4.5. Latin America
9.2.3.4.5.1. Market
Forecast, 2022
- 2030
9.2.4. Focal Segmental Glomerulosclerosis (FSGS)
9.2.4.1. Definition
9.2.4.2. Market
Forecast, 2022
- 2030
9.2.4.3. Compound Annual Growth Rate (CAGR)
9.2.4.4. Regional Bifurcation
9.2.4.4.1. North America
9.2.4.4.1.1. Market
Forecast, 2022
- 2030
9.2.4.4.2. Europe
9.2.4.4.2.1. Market
Forecast, 2022
- 2030
9.2.4.4.3. Asia Pacific
9.2.4.4.3.1. Market
Forecast, 2022
- 2030
9.2.4.4.4. Middle East and Africa
9.2.4.4.4.1. Market
Forecast, 2022
- 2030
9.2.4.4.5. Latin America
9.2.4.4.5.1. Market
Forecast, 2022
- 2030
9.2.5. Others
9.2.5.1. Definition
9.2.5.2. Market
Forecast, 2022
- 2030
9.2.5.3. Compound Annual Growth Rate (CAGR)
9.2.5.4. Regional Bifurcation
9.2.5.4.1. North America
9.2.5.4.1.1. Market
Forecast, 2022
- 2030
9.2.5.4.2. Europe
9.2.5.4.2.1. Market
Forecast, 2022
- 2030
9.2.5.4.3. Asia Pacific
9.2.5.4.3.1. Market
Forecast, 2022
- 2030
9.2.5.4.4. Middle East and Africa
9.2.5.4.4.1. Market
Forecast, 2022
- 2030
9.2.5.4.5. Latin America
9.2.5.4.5.1. Market
Forecast, 2022
- 2030
9.3.
Key Segment for Channeling Investments
9.3.1. By Application
10. Global
Bioartificial Kidney Market Analysis and Forecasts,
2022 – 2030
10.1. Overview
10.2. Global Bioartificial Kidney
Market Revenue (US$ Mn) and Forecasts,
By End User
10.2.1. Hospital
10.2.1.1. Definition
10.2.1.2. Market
Forecast, 2022
- 2030
10.2.1.3. Compound Annual Growth Rate (CAGR)
10.2.1.4. Regional Bifurcation
10.2.1.4.1. North America
10.2.1.4.1.1. Market
Forecast, 2022
- 2030
10.2.1.4.2. Europe
10.2.1.4.2.1. Market
Forecast, 2022
- 2030
10.2.1.4.3. Asia Pacific
10.2.1.4.3.1.
Market Forecast, 2022
- 2030 10.2.1.4.4. Middle East and Africa
10.2.1.4.4.1. Market Forecast, 2022
- 2030
10.2.1.4.5. Latin America
10.2.1.4.5.1. Market
Forecast, 2022
- 2030
10.2.2. Organ Transplant Centers
10.2.2.1. Definition
10.2.2.2. Market
Forecast, 2022
- 2030
10.2.2.3. Compound Annual Growth Rate (CAGR)
10.2.2.4. Regional Bifurcation
10.2.2.4.1. North America
10.2.2.4.1.1. Market
Forecast, 2022
- 2030
10.2.2.4.2. Europe
10.2.2.4.2.1. Market
Forecast, 2022
- 2030
10.2.2.4.3. Asia Pacific
10.2.2.4.3.1.
Market Forecast, 2022
- 2030 10.2.2.4.4. Middle East and Africa
10.2.2.4.4.1. Market Forecast, 2022 - 2030
10.2.2.4.5. Latin America
10.2.2.4.5.1. Market
Forecast, 2022
- 2030
10.2.3.
Research Institutes
10.2.3.1. Definition
10.2.3.2. Market
Forecast, 2022
- 2030
10.2.3.3. Compound Annual Growth Rate (CAGR)
10.2.3.4. Regional Bifurcation
10.2.3.4.1. North America
10.2.3.4.1.1. Market
Forecast, 2022
- 2030
10.2.3.4.2. Europe
10.2.3.4.2.1. Market
Forecast, 2022
- 2030
10.2.3.4.3. Asia Pacific
10.2.3.4.3.1.
Market Forecast, 2022
- 2030 10.2.3.4.4. Middle East and Africa
10.2.3.4.4.1. Market Forecast, 2022 - 2030
10.2.3.4.5. Latin America
10.2.3.4.5.1. Market
Forecast, 2022
- 2030
10.2.4. Others
10.2.4.1. Definition
10.2.4.2. Market
Forecast, 2022
- 2030
10.2.4.3. Compound Annual Growth Rate (CAGR)
10.2.4.4. Regional Bifurcation
10.2.4.4.1. North America
10.2.4.4.1.1. Market
Forecast, 2022
- 2030
10.2.4.4.2. Europe
10.2.4.4.2.1. Market
Forecast, 2022
- 2030
10.2.4.4.3. Asia Pacific
10.2.4.4.3.1.
Market Forecast, 2022
- 2030 10.2.4.4.4. Middle East and Africa
10.2.4.4.4.1. Market Forecast, 2022 - 2030
10.2.4.4.5. Latin America
10.2.4.4.5.1. Market
Forecast, 2022
- 2030
10.3. Key
Segment for Channeling Investments
10.3.1. By End User
11. North
America Bioartificial Kidney Market Analysis and Forecasts, 2022 - 2030
11.1. Overview
11.1.1. North America Bioartificial
Kidney Market Revenue (US$ Mn)
11.2. North
America Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
11.2.1. Pre-Clinical
11.2.2. Phase I clinical trial
11.2.3. Others
11.3. North America Bioartificial
Kidney Market Revenue (US$ Mn) and Forecasts,
By Application
11.3.1. Short-term solution of renal
dialysis
11.3.2. Longer-term of a living
kidney transplant
11.3.3. Polycystic Kidney Disease
11.3.4. Focal Segmental Glomerulosclerosis (FSGS)
11.3.5. Others
11.4. North America Bioartificial
Kidney Market Revenue (US$ Mn) and Forecasts,
By End User
11.4.1. Hospital
11.4.2. Organ Transplant Centers
11.4.3. Research Institutes
11.4.4. Others
11.5. North America Bioartificial
Kidney Market Revenue (US$ Mn) and Forecasts,
By Country
11.5.1. U.S
11.5.1.1.
U.S Bioartificial Kidney
Market Revenue (US$ Mn) and Forecasts,
By Clinical Trial
11.5.1.1.1.
Pre-Clinical 11.5.1.1.2. Phase I clinical trial
11.5.1.1.3. Others
11.5.1.2.
U.S Bioartificial Kidney
Market Revenue (US$ Mn) and Forecasts,
By Application
11.5.1.2.1.
Short-term solution of
renal dialysis 11.5.1.2.2. Longer-term of
a living kidney transplant
11.5.1.2.3. Polycystic Kidney Disease
11.5.1.2.4.
Focal Segmental Glomerulosclerosis (FSGS) 11.5.1.2.5. Others
11.5.1.3.
U.S Bioartificial Kidney
Market Revenue (US$ Mn) and Forecasts,
By End User
11.5.1.3.1. Hospital
11.5.1.3.2.
Organ Transplant Centers 11.5.1.3.3. Research Institutes
11.5.1.3.4. Others
11.5.2. Canada
11.5.2.1.
Canada Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
11.5.2.1.1.
Pre-Clinical 11.5.2.1.2. Phase I clinical trial
11.5.2.1.3. Others
11.5.2.2.
Canada Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application
11.5.2.2.1.
Short-term solution of
renal dialysis 11.5.2.2.2. Longer-term of
a living kidney transplant
11.5.2.2.3. Polycystic Kidney Disease
11.5.2.2.4.
Focal Segmental Glomerulosclerosis (FSGS) 11.5.2.2.5. Others
11.5.2.3.
Canada Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User
11.5.2.3.1. Hospital
11.5.2.3.2.
Organ Transplant Centers 11.5.2.3.3. Research Institutes
11.5.2.3.4. Others
11.5.3.
Mexico
11.5.3.1.
Mexico Bioartificial Kidney Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial
11.5.3.1.1.
Pre-Clinical 11.5.3.1.2. Phase I clinical trial
11.5.3.1.3. Others
11.5.3.2.
Mexico Bioartificial Kidney Market Revenue (US$ Mn) and
Forecasts, By Application
11.5.3.2.1.
Short-term solution of
renal dialysis 11.5.3.2.2. Longer-term of
a living kidney transplant
11.5.3.2.3. Polycystic Kidney Disease
11.5.3.2.4.
Focal Segmental Glomerulosclerosis (FSGS) 11.5.3.2.5. Others
11.5.3.3.
Mexico Bioartificial Kidney Market Revenue (US$ Mn) and
Forecasts, By End User
11.5.3.3.1. Hospital
11.5.3.3.2.
Organ Transplant Centers 11.5.3.3.3. Research Institutes
11.5.3.3.4. Others
11.5.4. Rest of North America
11.5.4.1.
Rest of North
America Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
11.5.4.1.1.
Pre-Clinical 11.5.4.1.2. Phase I clinical trial
11.5.4.1.3. Others
11.5.4.2.
Rest of North
America Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application
11.5.4.2.1.
Short-term solution of
renal dialysis 11.5.4.2.2. Longer-term of
a living kidney transplant
11.5.4.2.3. Polycystic Kidney Disease
11.5.4.2.4.
Focal Segmental Glomerulosclerosis (FSGS) 11.5.4.2.5. Others
11.5.4.3.
Rest of North
America Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User
11.5.4.3.1. Hospital
11.5.4.3.2.
Organ Transplant Centers 11.5.4.3.3. Research Institutes
11.5.4.3.4. Others
11.6. Key Segment for Channeling Investments
11.6.1. By Country
11.6.2. By Clinical Trial
11.6.3. By Application
11.6.4. By End User
12. Europe
Bioartificial Kidney Market Analysis and Forecasts,
2022 - 2030
12.1. Overview
12.1.1. Europe Bioartificial Kidney Market Revenue (US$ Mn)
12.2. Europe Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
12.2.1. Pre-Clinical
12.2.2. Phase I clinical trial
12.2.3. Others
12.3. Europe Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application
12.3.1. Short-term solution of renal
dialysis
12.3.2. Longer-term of a living
kidney transplant
12.3.3. Polycystic Kidney Disease
12.3.4. Focal Segmental Glomerulosclerosis (FSGS)
12.3.5. Others
12.4. Europe Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User
12.4.1. Hospital
12.4.2. Organ Transplant Centers
12.4.3. Research Institutes
12.4.4. Others
12.5. Europe Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts,
By Country
12.5.1. France
12.5.1.1.
France Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
12.5.1.1.1.
Pre-Clinical 12.5.1.1.2. Phase I clinical trial
12.5.1.1.3. Others
12.5.1.2.
France Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application
12.5.1.2.1.
Short-term solution of
renal dialysis 12.5.1.2.2. Longer-term of
a living kidney transplant
12.5.1.2.3. Polycystic Kidney Disease
12.5.1.2.4.
Focal Segmental Glomerulosclerosis (FSGS) 12.5.1.2.5. Others
12.5.1.3.
France Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User
12.5.1.3.1. Hospital
12.5.1.3.2.
Organ Transplant Centers 12.5.1.3.3. Research Institutes
12.5.1.3.4. Others
12.5.2. The UK
12.5.2.1.
The UK
Bioartificial Kidney Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial
12.5.2.1.1.
Pre-Clinical 12.5.2.1.2. Phase I clinical trial
12.5.2.1.3. Others
12.5.2.2.
The UK
Bioartificial Kidney Market Revenue (US$ Mn) and
Forecasts, By Application
12.5.2.2.1.
Short-term solution of
renal dialysis 12.5.2.2.2. Longer-term of
a living kidney transplant
12.5.2.2.3. Polycystic Kidney Disease
12.5.2.2.4.
Focal Segmental Glomerulosclerosis (FSGS) 12.5.2.2.5. Others
12.5.2.3.
The UK
Bioartificial Kidney Market Revenue (US$ Mn) and
Forecasts, By End User
12.5.2.3.1. Hospital
12.5.2.3.2.
Organ Transplant Centers 12.5.2.3.3. Research Institutes
12.5.2.3.4. Others
12.5.3. Spain
12.5.3.1.
Spain Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
12.5.3.1.1.
Pre-Clinical 12.5.3.1.2. Phase I clinical trial
12.5.3.1.3. Others
12.5.3.2.
Spain Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application
12.5.3.2.1.
Short-term solution of
renal dialysis 12.5.3.2.2. Longer-term of
a living kidney transplant
12.5.3.2.3. Polycystic Kidney Disease
12.5.3.2.4.
Focal Segmental Glomerulosclerosis (FSGS) 12.5.3.2.5. Others
12.5.3.3.
Spain Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User
12.5.3.3.1. Hospital
12.5.3.3.2.
Organ Transplant Centers 12.5.3.3.3. Research Institutes
12.5.3.3.4. Others
12.5.4. Germany
12.5.4.1.
Germany Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
12.5.4.1.1.
Pre-Clinical 12.5.4.1.2. Phase I clinical trial
12.5.4.1.3. Others
12.5.4.2.
Germany Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application
12.5.4.2.1.
Short-term solution of
renal dialysis 12.5.4.2.2. Longer-term of
a living kidney transplant
12.5.4.2.3. Polycystic Kidney Disease
12.5.4.2.4.
Focal Segmental Glomerulosclerosis (FSGS) 12.5.4.2.5. Others
12.5.4.3.
Germany Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User
12.5.4.3.1. Hospital
12.5.4.3.2.
Organ Transplant Centers 12.5.4.3.3. Research Institutes
12.5.4.3.4. Others
12.5.5. Italy
12.5.5.1.
Italy Bioartificial Kidney Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial
12.5.5.1.1.
Pre-Clinical 12.5.5.1.2. Phase I clinical trial
12.5.5.1.3. Others
12.5.5.2.
Italy Bioartificial Kidney Market Revenue (US$ Mn) and
Forecasts, By Application
12.5.5.2.1.
Short-term solution of
renal dialysis 12.5.5.2.2. Longer-term of
a living kidney transplant
12.5.5.2.3. Polycystic Kidney Disease
12.5.5.2.4.
Focal Segmental Glomerulosclerosis (FSGS) 12.5.5.2.5. Others
12.5.5.3.
Italy Bioartificial Kidney Market Revenue (US$ Mn) and
Forecasts, By End User
12.5.5.3.1. Hospital
12.5.5.3.2.
Organ Transplant Centers 12.5.5.3.3. Research Institutes
12.5.5.3.4. Others
12.5.6. Nordic Countries
12.5.6.1.
Nordic Countries Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
12.5.6.1.1.
Pre-Clinical 12.5.6.1.2. Phase I clinical trial
12.5.6.1.3. Others
12.5.6.2.
Nordic Countries Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application
12.5.6.2.1.
Short-term solution of
renal dialysis 12.5.6.2.2. Longer-term of
a living kidney transplant
12.5.6.2.3. Polycystic Kidney Disease
12.5.6.2.4.
Focal Segmental Glomerulosclerosis (FSGS) 12.5.6.2.5. Others
12.5.6.3.
Nordic Countries Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User
12.5.6.3.1. Hospital
12.5.6.3.2.
Organ Transplant Centers 12.5.6.3.3. Research Institutes
12.5.6.3.4. Others
12.5.6.4.
Nordic Countries Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux Union
12.5.7.1.
Benelux Union Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
12.5.7.1.1.
Pre-Clinical 12.5.7.1.2. Phase I clinical trial
12.5.7.1.3. Others
12.5.7.2.
Benelux Union Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application
12.5.7.2.1.
Short-term solution of
renal dialysis 12.5.7.2.2. Longer-term of
a living kidney transplant
12.5.7.2.3. Polycystic Kidney Disease
12.5.7.2.4. Focal Segmental Glomerulosclerosis (FSGS)
12.5.7.2.5. Others
12.5.7.3.
Benelux Union Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User
12.5.7.3.1. Hospital
12.5.7.3.2.
Organ Transplant Centers 12.5.7.3.3. Research Institutes
12.5.7.3.4. Others
12.5.7.4.
Benelux Union Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Country
12.5.7.4.1. Belgium
12.5.7.4.2. The Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of Europe
12.5.8.1.
Rest of Europe
Bioartificial Kidney Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial
12.5.8.1.1.
Pre-Clinical 12.5.8.1.2. Phase I clinical trial
12.5.8.1.3. Others
12.5.8.2.
Rest of Europe
Bioartificial Kidney Market Revenue (US$ Mn) and
Forecasts, By Application
12.5.8.2.1.
Short-term solution of
renal dialysis 12.5.8.2.2. Longer-term of
a living kidney transplant
12.5.8.2.3. Polycystic Kidney Disease
12.5.8.2.4.
Focal Segmental Glomerulosclerosis (FSGS) 12.5.8.2.5. Others
12.5.8.3.
Rest of Europe
Bioartificial Kidney Market Revenue (US$ Mn) and
Forecasts, By End User
12.5.8.3.1. Hospital
12.5.8.3.2.
Organ Transplant Centers 12.5.8.3.3. Research Institutes
12.5.8.3.4. Others
12.6. Key Segment for Channeling Investments
12.6.1. By Country
12.6.2. By Clinical Trial
12.6.3. By Application
12.6.4. By End User
13. Asia
Pacific Bioartificial Kidney Market
Analysis and Forecasts, 2022 - 2030
13.1. Overview
13.1.1. Asia Pacific Bioartificial
Kidney Market Revenue (US$ Mn)
13.2. Asia Pacific Bioartificial
Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
13.2.1. Pre-Clinical
13.2.2. Phase I clinical trial
13.2.3. Others
13.3. Asia Pacific Bioartificial
Kidney Market Revenue (US$ Mn) and Forecasts, By Application
13.3.1. Short-term solution of renal
dialysis
13.3.2. Longer-term of a living
kidney transplant
13.3.3. Polycystic Kidney Disease
13.3.4. Focal Segmental Glomerulosclerosis (FSGS)
13.3.5. Others
13.4. Asia Pacific Bioartificial
Kidney Market Revenue (US$ Mn) and Forecasts, By End User
13.4.1. Hospital
13.4.2. Organ Transplant Centers
13.4.3. Research Institutes
13.4.4. Others
13.5. Asia Pacific Bioartificial
Kidney Market Revenue (US$ Mn) and Forecasts, By Country
13.5.1. China
13.5.1.1.
China Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts,
By Clinical Trial
13.5.1.1.1.
Pre-Clinical 13.5.1.1.2. Phase I clinical trial
13.5.1.1.3. Others
13.5.1.2.
China Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts,
By Application
13.5.1.2.1.
Short-term solution of
renal dialysis 13.5.1.2.2. Longer-term of
a living kidney transplant
13.5.1.2.3. Polycystic Kidney Disease
13.5.1.2.4.
Focal Segmental Glomerulosclerosis (FSGS) 13.5.1.2.5. Others
13.5.1.3.
China Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts,
By End User
13.5.1.3.1. Hospital
13.5.1.3.2.
Organ Transplant Centers 13.5.1.3.3. Research Institutes
13.5.1.3.4. Others
13.5.2. Japan
13.5.2.1.
Japan Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts,
By Clinical Trial
13.5.2.1.1.
Pre-Clinical 13.5.2.1.2. Phase I clinical trial
13.5.2.1.3. Others
13.5.2.2.
Japan Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts,
By Application
13.5.2.2.1.
Short-term solution of
renal dialysis 13.5.2.2.2. Longer-term of
a living kidney transplant
13.5.2.2.3. Polycystic Kidney Disease
13.5.2.2.4.
Focal Segmental Glomerulosclerosis (FSGS) 13.5.2.2.5. Others
13.5.2.3.
Japan Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts,
By End User
13.5.2.3.1. Hospital
13.5.2.3.2.
Organ Transplant Centers 13.5.2.3.3. Research Institutes
13.5.2.3.4. Others
13.5.3. India
13.5.3.1.
India Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
13.5.3.1.1.
Pre-Clinical 13.5.3.1.2. Phase I clinical trial
13.5.3.1.3. Others
13.5.3.2.
India Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application
13.5.3.2.1.
Short-term solution of
renal dialysis 13.5.3.2.2. Longer-term of
a living kidney transplant
13.5.3.2.3. Polycystic Kidney Disease
13.5.3.2.4.
Focal Segmental Glomerulosclerosis (FSGS) 13.5.3.2.5. Others
13.5.3.3.
India Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User
13.5.3.3.1. Hospital
13.5.3.3.2.
Organ Transplant Centers 13.5.3.3.3. Research Institutes
13.5.3.3.4. Others
13.5.4. New Zealand
13.5.4.1.
New Zealand Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
13.5.4.1.1.
Pre-Clinical 13.5.4.1.2. Phase I clinical trial
13.5.4.1.3. Others
13.5.4.2.
New Zealand Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application
13.5.4.2.1.
Short-term solution of
renal dialysis 13.5.4.2.2. Longer-term of
a living kidney transplant
13.5.4.2.3. Polycystic Kidney Disease
13.5.4.2.4.
Focal Segmental Glomerulosclerosis (FSGS) 13.5.4.2.5. Others
13.5.4.3.
New Zealand Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User
13.5.4.3.1. Hospital
13.5.4.3.2.
Organ Transplant Centers 13.5.4.3.3. Research Institutes
13.5.4.3.4. Others
13.5.5. Australia
13.5.5.1.
Australia Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
13.5.5.1.1.
Pre-Clinical 13.5.5.1.2. Phase I clinical trial
13.5.5.1.3. Others
13.5.5.2.
Australia Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application
13.5.5.2.1.
Short-term solution of
renal dialysis 13.5.5.2.2. Longer-term of
a living kidney transplant
13.5.5.2.3. Polycystic Kidney Disease
13.5.5.2.4.
Focal Segmental Glomerulosclerosis (FSGS) 13.5.5.2.5. Others
13.5.5.3.
Australia Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User
13.5.5.3.1. Hospital
13.5.5.3.2.
Organ Transplant Centers 13.5.5.3.3. Research Institutes
13.5.5.3.4. Others
13.5.6. South Korea
13.5.6.1.
South Korea Bioartificial
Kidney Market Revenue (US$ Mn) and Forecasts,
By Clinical Trial
13.5.6.1.1.
Pre-Clinical 13.5.6.1.2. Phase I clinical trial
13.5.6.1.3. Others
13.5.6.2.
South Korea Bioartificial
Kidney Market Revenue (US$ Mn) and Forecasts,
By Application
13.5.6.2.1.
Short-term solution of
renal dialysis 13.5.6.2.2. Longer-term of
a living kidney transplant
13.5.6.2.3. Polycystic Kidney Disease
13.5.6.2.4.
Focal Segmental Glomerulosclerosis (FSGS) 13.5.6.2.5. Others
13.5.6.3.
South Korea Bioartificial
Kidney Market Revenue (US$ Mn) and Forecasts,
By End User
13.5.6.3.1. Hospital
13.5.6.3.2.
Organ Transplant Centers 13.5.6.3.3. Research Institutes
13.5.6.3.4. Others
13.5.7. Southeast Asia
13.5.7.1.
Southeast Asia Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
13.5.7.1.1.
Pre-Clinical 13.5.7.1.2. Phase I clinical trial 13.5.7.1.3. Others
13.5.7.2.
Southeast Asia Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application
13.5.7.2.1.
Short-term solution of
renal dialysis 13.5.7.2.2. Longer-term of
a living kidney transplant
13.5.7.2.3. Polycystic Kidney Disease
13.5.7.2.4.
Focal Segmental Glomerulosclerosis (FSGS) 13.5.7.2.5. Others
13.5.7.3.
Southeast Asia Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User
13.5.7.3.1. Hospital
13.5.7.3.2.
Organ Transplant Centers 13.5.7.3.3. Research Institutes
13.5.7.3.4. Others
13.5.7.4.
Southeast Asia Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest of Southeast Asia
13.5.8. Rest of Asia Pacific
13.5.8.1.
Rest of Asia
Pacific Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
13.5.8.1.1.
Pre-Clinical 13.5.8.1.2. Phase I clinical trial
13.5.8.1.3. Others
13.5.8.2.
Rest of Asia
Pacific Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application
13.5.8.2.1.
Short-term solution of
renal dialysis 13.5.8.2.2. Longer-term of
a living kidney transplant
13.5.8.2.3. Polycystic Kidney Disease
13.5.8.2.4.
Focal Segmental Glomerulosclerosis (FSGS) 13.5.8.2.5. Others
13.5.8.3.
Rest of Asia
Pacific Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User
13.5.8.3.1. Hospital
13.5.8.3.2.
Organ Transplant Centers 13.5.8.3.3. Research Institutes
13.5.8.3.4. Others
13.6. Key Segment for Channeling Investments
13.6.1. By Country
13.6.2. By Clinical Trial
13.6.3. By Application
13.6.4. By End User
14. Middle
East and Africa Bioartificial Kidney Market
Analysis and Forecasts, 2022 - 2030
14.1. Overview
14.1.1. Middle East and Africa Bioartificial Kidney Market Revenue (US$ Mn)
14.2. Middle East
and Africa Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
14.2.1. Pre-Clinical
14.2.2. Phase I clinical trial
14.2.3. Others
14.3. Middle East
and Africa Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application
14.3.1. Short-term solution of renal
dialysis
14.3.2. Longer-term of a living
kidney transplant
14.3.3. Polycystic Kidney Disease
14.3.4. Focal Segmental Glomerulosclerosis (FSGS)
14.3.5. Others
14.4. Middle East
and Africa Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User
14.4.1. Hospital
14.4.2. Organ Transplant Centers
14.4.3. Research Institutes
14.4.4. Others
14.5. Middle East
and Africa Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Country
14.5.1. Saudi Arabia
14.5.1.1.
Saudi Arabia Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
14.5.1.1.1.
Pre-Clinical 14.5.1.1.2. Phase I clinical trial
14.5.1.1.3. Others
14.5.1.2.
Saudi Arabia Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application
14.5.1.2.1.
Short-term solution of
renal dialysis 14.5.1.2.2. Longer-term of
a living kidney transplant
14.5.1.2.3. Polycystic Kidney Disease
14.5.1.2.4.
Focal Segmental Glomerulosclerosis (FSGS) 14.5.1.2.5. Others
14.5.1.3.
Saudi Arabia Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User
14.5.1.3.1. Hospital
14.5.1.3.2.
Organ Transplant Centers 14.5.1.3.3. Research Institutes
14.5.1.3.4. Others
14.5.2. UAE
14.5.2.1.
UAE Bioartificial Kidney Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial
14.5.2.1.1.
Pre-Clinical 14.5.2.1.2. Phase I clinical trial
14.5.2.1.3. Others
14.5.2.2.
UAE Bioartificial Kidney Market Revenue (US$ Mn) and
Forecasts, By Application
14.5.2.2.1.
Short-term solution of
renal dialysis 14.5.2.2.2. Longer-term of
a living kidney transplant 14.5.2.2.3.
Polycystic Kidney Disease
14.5.2.2.4.
Focal Segmental Glomerulosclerosis (FSGS) 14.5.2.2.5. Others
14.5.2.3.
UAE Bioartificial Kidney Market Revenue (US$ Mn) and
Forecasts, By End User
14.5.2.3.1. Hospital
14.5.2.3.2.
Organ Transplant Centers 14.5.2.3.3. Research Institutes
14.5.2.3.4. Others
14.5.3. Egypt
14.5.3.1.
Egypt Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
14.5.3.1.1.
Pre-Clinical 14.5.3.1.2. Phase I clinical trial
14.5.3.1.3. Others
14.5.3.2.
Egypt Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application
14.5.3.2.1.
Short-term solution of
renal dialysis 14.5.3.2.2. Longer-term of
a living kidney transplant
14.5.3.2.3. Polycystic Kidney Disease
14.5.3.2.4.
Focal Segmental Glomerulosclerosis (FSGS) 14.5.3.2.5. Others
14.5.3.3.
Egypt Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User
14.5.3.3.1. Hospital
14.5.3.3.2.
Organ Transplant Centers 14.5.3.3.3. Research Institutes
14.5.3.3.4. Others
14.5.4. Kuwait
14.5.4.1.
Kuwait Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
14.5.4.1.1.
Pre-Clinical 14.5.4.1.2. Phase I clinical trial
14.5.4.1.3. Others
14.5.4.2.
Kuwait Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application
14.5.4.2.1.
Short-term solution of
renal dialysis 14.5.4.2.2. Longer-term of
a living kidney transplant
14.5.4.2.3. Polycystic Kidney Disease
14.5.4.2.4.
Focal Segmental Glomerulosclerosis (FSGS) 14.5.4.2.5. Others
14.5.4.3.
Kuwait Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User
14.5.4.3.1. Hospital
14.5.4.3.2.
Organ Transplant Centers 14.5.4.3.3. Research Institutes
14.5.4.3.4. Others
14.5.5. South Africa
14.5.5.1.
South Africa Bioartificial Kidney Market Revenue (US$
Mn) and Forecasts, By Clinical Trial
14.5.5.1.1.
Pre-Clinical 14.5.5.1.2. Phase I clinical trial
14.5.5.1.3. Others
14.5.5.2.
South Africa Bioartificial Kidney Market Revenue (US$
Mn) and Forecasts, By Application
14.5.5.2.1.
Short-term solution of
renal dialysis 14.5.5.2.2. Longer-term of
a living kidney transplant
14.5.5.2.3. Polycystic Kidney Disease
14.5.5.2.4.
Focal Segmental Glomerulosclerosis (FSGS) 14.5.5.2.5. Others
14.5.5.3.
South Africa Bioartificial Kidney Market Revenue (US$
Mn) and Forecasts, By End User
14.5.5.3.1. Hospital
14.5.5.3.2.
Organ Transplant Centers 14.5.5.3.3. Research Institutes
14.5.5.3.4. Others
14.5.6. Rest of Middle East & Africa
14.5.6.1.
Rest of Middle
East & Africa Bioartificial Kidney Market
Revenue (US$ Mn) and
Forecasts, By Clinical Trial
14.5.6.1.1.
Pre-Clinical 14.5.6.1.2. Phase I clinical trial
14.5.6.1.3. Others
14.5.6.2.
Rest of Middle
East & Africa Bioartificial Kidney Market
Revenue (US$ Mn) and
Forecasts, By Application
14.5.6.2.1.
Short-term solution of
renal dialysis 14.5.6.2.2. Longer-term of
a living kidney transplant
14.5.6.2.3. Polycystic Kidney Disease
14.5.6.2.4.
Focal Segmental Glomerulosclerosis (FSGS) 14.5.6.2.5. Others
14.5.6.3.
Rest of Middle
East & Africa Bioartificial Kidney Market
Revenue (US$ Mn) and
Forecasts, By End User
14.5.6.3.1. Hospital
14.5.6.3.2.
Organ Transplant Centers 14.5.6.3.3. Research Institutes
14.5.6.3.4. Others
14.6. Key Segment for Channeling Investments
14.6.1. By Country
14.6.2. By Clinical Trial
14.6.3. By Application
14.6.4. By End User
15. Latin
America Bioartificial Kidney Market Analysis and Forecasts, 2022 - 2030
15.1. Overview
15.1.1. Latin America Bioartificial
Kidney Market Revenue (US$ Mn)
15.2. Latin America Bioartificial
Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
15.2.1. Pre-Clinical
15.2.2. Phase I clinical trial
15.2.3. Others
15.3. Latin America Bioartificial
Kidney Market Revenue (US$ Mn) and Forecasts, By Application
15.3.1. Short-term solution of renal
dialysis
15.3.2. Longer-term of a living
kidney transplant
15.3.3. Polycystic Kidney Disease
15.3.4. Focal Segmental Glomerulosclerosis (FSGS)
15.3.5. Others
15.4. Latin America Bioartificial
Kidney Market Revenue (US$ Mn) and Forecasts, By End User
15.4.1. Hospital
15.4.2. Organ Transplant Centers
15.4.3. Research Institutes
15.4.4. Others
15.5. Latin America Bioartificial
Kidney Market Revenue (US$ Mn) and Forecasts, By Country
15.5.1. Brazil
15.5.1.1.
Brazil Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Clinical Trial
15.5.1.1.1.
Pre-Clinical 15.5.1.1.2. Phase I clinical trial
15.5.1.1.3. Others
15.5.1.2.
Brazil Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By Application
15.5.1.2.1.
Short-term solution of
renal dialysis 15.5.1.2.2. Longer-term of
a living kidney transplant 15.5.1.2.3.
Polycystic Kidney Disease
15.5.1.2.4.
Focal Segmental Glomerulosclerosis (FSGS) 15.5.1.2.5. Others
15.5.1.3.
Brazil Bioartificial Kidney Market Revenue (US$ Mn) and Forecasts, By End User
15.5.1.3.1. Hospital
15.5.1.3.2.
Organ Transplant Centers 15.5.1.3.3. Research Institutes
15.5.1.3.4. Others
15.5.2. Argentina
15.5.2.1.
Argentina Bioartificial Kidney Market Revenue (US$ Mn) and
Forecasts, By Clinical Trial
15.5.2.1.1.
Pre-Clinical 15.5.2.1.2. Phase I clinical trial
15.5.2.1.3. Others
15.5.2.2.
Argentina Bioartificial Kidney Market Revenue (US$ Mn) and
Forecasts, By Application
15.5.2.2.1.
Short-term solution of
renal dialysis 15.5.2.2.2. Longer-term of
a living kidney transplant
15.5.2.2.3. Polycystic Kidney Disease
15.5.2.2.4.
Focal Segmental Glomerulosclerosis (FSGS) 15.5.2.2.5. Others
15.5.2.3.
Argentina Bioartificial Kidney Market Revenue (US$ Mn) and
Forecasts, By End User
15.5.2.3.1. Hospital
15.5.2.3.2.
Organ Transplant Centers 15.5.2.3.3. Research Institutes
15.5.2.3.4. Others
15.5.3. Rest of Latin America
15.5.3.1.
Rest of Latin
America Bioartificial Kidney Market Revenue
(US$ Mn) and Forecasts, By Clinical Trial
15.5.3.1.1.
Pre-Clinical 15.5.3.1.2. Phase I clinical trial
15.5.3.1.3. Others
15.5.3.2.
Rest of Latin
America Bioartificial Kidney Market Revenue
(US$ Mn) and Forecasts, By Application
15.5.3.2.1.
Short-term solution of
renal dialysis 15.5.3.2.2. Longer-term of
a living kidney transplant
15.5.3.2.3. Polycystic Kidney Disease
15.5.3.2.4.
Focal Segmental Glomerulosclerosis (FSGS) 15.5.3.2.5. Others
15.5.3.3.
Rest of Latin
America Bioartificial Kidney Market Revenue
(US$ Mn) and Forecasts, By End User
15.5.3.3.1. Hospital
15.5.3.3.2.
Organ Transplant Centers 15.5.3.3.3. Research Institutes
15.5.3.3.4. Others
15.6. Key Segment for Channeling Investments
15.6.1. By Country
15.6.2. By Clinical Trial
15.6.3. By Application
15.6.4. By End User
16. Competitive Benchmarking
16.1. Global Presence and Growth Strategies
16.1.1. Mergers
and Acquisitions
16.1.2. Product Launches
16.1.3. Investments Trends
16.1.4. R&D Initiatives
17. Player Profiles
17.1. AWAK Technologies
17.1.1. Company Details
17.1.2. Company Overview
17.1.3. Product Offerings
17.1.4. Key Developments
17.1.5. Financial Analysis
17.1.6. SWOT Analysis
17.1.7. Business Strategies
17.2. Blood Purification Technologies Inc.
17.2.1. Company Details
17.2.2. Company Overview
17.2.3. Product Offerings
17.2.4. Key Developments
17.2.5. Financial Analysis
17.2.6. SWOT Analysis
17.2.7. Business Strategies
17.3. Dutch Kidney Foundation
17.3.1. Company Details
17.3.2. Company Overview
17.3.3. Product Offerings
17.3.4. Key Developments
17.3.5. Financial Analysis
17.3.6. SWOT Analysis
17.3.7. Business Strategies
17.4. UCSF
17.4.1. Company Details
17.4.2. Company Overview
17.4.3. Product Offerings
17.4.4. Key Developments
17.4.5. Financial Analysis
17.4.6. SWOT Analysis
17.4.7. Business Strategies
17.5. Other Market Participants
18. Key Findings
Note: This
ToC is tentative and can be changed according to the research study conducted during the course of
report completion.
**Exclusive for Multi-User and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com


Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.
